These analysts also forecasted Growth Estimates for the Current Quarter for ADAP to be 37.8%. They are projecting Next Quarter growth of 17.86%. For the next 5 years, Adaptimmune Therapeutics plc is expecting Growth of -12.09% per annum, whereas in the past 5 years the growth was 31.06% per annum.
Some buy side analysts are also providing their Analysis on Adaptimmune Therapeutics plc, where 1 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 0 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)
The Relative Volume of the company is 0.29 and Average Volume (3 months) is 3.2 million. The company’s P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0.
The company shows its Return on Assets (ROA) value of -42.7%. The Return on Equity (ROE) value stands at -58.6%. While it’s Return on Investment (ROI) value is -113.3%.
While looking at the Stock’s Performance, Adaptimmune Therapeutics plc currently shows a Weekly Performance of 0.38%, where Monthly Performance is -6.21%, Quarterly performance is 72.26%, 6 Months performance is 99.25% and yearly performance percentage is 448.63%. Year to Date performance value (YTD perf) value is 567.5%. The Stock currently has a Weekly Volatility of 6.54% and Monthly Volatility of 6.77%.